October 20, 2011

Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis

- New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress -
- U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS -

 

Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
- New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress -
- U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS -

Paris, France – October 20, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile and efficacy of teriflunomide over a six-year period after the initial randomization. A total of fifteen presentations on teriflunomide are on the program for the fifth joint triennial congress of the European and American Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS / ACTRIMS) in Amsterdam, Netherlands.